Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Beth Overmoyer, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Tolaney SM, Barroso-Sousa R, Keenan T, Li T, Trippa L, Vaz-Luis I, Wulf G, Spring L, Sinclair NF, Andrews C, Pittenger J, Richardson ET, Dillon D, Lin NU, Overmoyer B, Partridge AH, Van Allen E, Mittendorf EA, Winer EP, Krop IE. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2020 Sep 03. PMID: 32880602.
    Citations:    
  2. White RE, Warren L, Nakhlis F, Rosenbluth J, Bellon J, Block C, Overmoyer B. Characteristics associated with inflammatory breast cancer (IBC): An epidemiologic study from a dedicated IBC program. Breast J. 2020 Sep 01. PMID: 32875655.
    Citations:    
  3. Jacene HA, DiPiro PJ, Bellon J, Hu J, Cheng SC, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth JM, Yeh E, Overmoyer B. Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning. Breast Cancer Res Treat. 2020 Jun; 181(2):383-390. PMID: 32318957.
    Citations:    
  4. Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Huang Bartlett C, Koehler M, Winer EP, Burstein HJ. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019 Sep; 30(9):1514-1520. PMID: 31987407.
    Citations:    
  5. Sharma MR, Mehrotra S, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Velasco M, Overmoyer B, Rugo HS, Ratain MJ, Gobburu JV. Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). J Clin Pharmacol. 2020 Apr; 60(4):444-452. PMID: 31802506.
    Citations:    
  6. Thomas R, Shinagare AB, Rosenthal MH, Lee B, Jacene HA, Johnston MA, Overmoyer BA. Computed tomographic assessment of lean body mass in patients on selective androgen receptor modulator. Clin Imaging. 2020 02; 59(2):100-103. PMID: 31812880.
    Citations:    
  7. Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Huang Bartlett C, Koehler M, Winer EP, Burstein HJ. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019 09 01; 30(9):1514-1520. PMID: 31250880.
    Citations:    
  8. Nakhlis F, Regan MM, Chun YS, Dominici LS, Caterson S, Bellon JR, Warren L, Yeh ED, Jacene HA, King TA, Overmoyer B. Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experience. Breast J. 2020 03; 26(3):384-390. PMID: 31448540.
    Citations:    
  9. Rosenbluth JM, Overmoyer BA. Inflammatory Breast Cancer: a Separate Entity. Curr Oncol Rep. 2019 08 15; 21(10):86. PMID: 31414257.
    Citations:    
  10. Singh J, Asad S, Zhang Y, Nock W, Adams E, Damicis A, Ramaswamy B, Williams N, Parsons HA, Adalsteinsson VA, Winer EP, Lin NU, Partridge AH, Overmoyer B, Stover DG. Aggressive Subsets of Metastatic Triple Negative Breast Cancer. Clin Breast Cancer. 2020 02; 20(1):e20-e26. PMID: 31631016.
    Citations:    
  11. Devi GR, Hough H, Barrett N, Cristofanilli M, Overmoyer B, Spector N, Ueno NT, Woodward W, Kirkpatrick J, Vincent B, Williams KP, Finley C, Duff B, Worthy V, McCall S, Hollister BA, Palmer G, Force J, Westbrook K, Fayanju O, Suneja G, Dent SF, Hwang ES, Patierno SR, Marcom PK. Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium. J Cancer. 2019; 10(15):3344-3351. PMID: 31293637.
    Citations:    
  12. Bellon JR, Guo H, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Hudis CA, Krop I, Burstein HJ, Winer EP, Tolaney SM. Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Res Treat. 2019 Jul; 176(2):303-310. PMID: 31004299.
    Citations:    
  13. Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, Partridge AH, Hudis CA, Krop IE, Burstein HJ, Winer EP. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019 08 01; 37(22):1868-1875. PMID: 30939096.
    Citations:    
  14. Rana HQ, Sacca R, Drogan C, Gutierrez S, Schlosnagle E, Regan MM, Speare V, LaDuca H, Dolinsky J, Garber JE, Overmoyer BA. Prevalence of germline variants in inflammatory breast cancer. Cancer. 2019 07 01; 125(13):2194-2202. PMID: 30933323.
    Citations:    
  15. Jacene HA, Youn T, DiPiro PJ, Hu J, Cheng SC, Franchetti Y, Shah H, Bellon JR, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth J, Yeh E, Overmoyer B. Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade. Clin Breast Cancer. 2019 04; 19(2):146-155. PMID: 30584057.
    Citations:    Fields:    
  16. Rashkin SR, Chua KC, Ho C, Mulkey F, Jiang C, Mushiroda T, Kubo M, Friedman PN, Rugo HS, McLeod HL, Ratain MJ, Castillos F, Naughton M, Overmoyer B, Toppmeyer D, Witte JS, Owzar K, Kroetz DL. A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance). Clin Pharmacol Ther. 2019 03; 105(3):738-745. PMID: 30260474.
    Citations:    Fields:    
  17. Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, Balko J, Xu Q, Bardia A, Tolaney SM, Gelman R, Lloyd M, Wang Y, Xu Y, Michor F, Wang V, Winer EP, Polyak K, Lin NU. Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer. 2018; 4:10. PMID: 29761158.
    Citations: 2     
  18. Guilbert MC, Overmoyer B, Lester SC. Pure Intralymphatic Invasion in the Absence of Stromal Invasion After Neoadjuvant Therapy: A Rare Pattern of Residual Breast Carcinoma. Am J Surg Pathol. 2018 05; 42(5):679-686. PMID: 29394169.
    Citations:    Fields:    
  19. Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M, Chang E, Lim B, Krishnamurthy S, Stauder MC, Parmar S, Mohamed MM, Alexander A, Valero V, Woodward WA. International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer. 2018; 9(8):1437-1447. PMID: 29721054.
    Citations:    
  20. Jagsi R, Griffith KA, Bellon JR, Woodward WA, Horton JK, Ho A, Feng FY, Speers C, Overmoyer B, Sabel M, Schott AF, Pierce L. Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study. J Clin Oncol. 2018 05 01; 36(13):1317-1322. PMID: 29558281.
    Citations:    Fields:    
  21. Woodward WA, Cristofanilli M, Merajver SD, Van Laere S, Pusztai L, Bertucci F, Berditchevski F, Polyak K, Overmoyer B, Devi GR, Sterneck E, Schneider R, Debeb BG, Wang X, van Golen KL, El-Zein R, Rahal OM, Alexander A, Reuben JM, Krishnamurthy S, Lucci A, Ueno NT. Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference. J Cancer. 2017; 8(17):3607-3614. PMID: 29667990.
    Citations:    
  22. Ma C, Frosch ZA, Overmoyer B, Cooper AZ. Vocal fold paralysis on positron emission tomography-CT. Thorax. 2018 01; 73(1):97-98. PMID: 28717033.
    Citations:    Fields:    Translation:Humans
  23. Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV. Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). AAPS J. 2017 09; 19(5):1411-1423. PMID: 28620884.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  24. Nakhlis F, Regan MM, Warren LE, Bellon JR, Hirshfield-Bartek J, Duggan MM, Dominici LS, Golshan M, Jacene HA, Yeh ED, Mullaney EE, Overmoyer B. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer. Ann Surg Oncol. 2017 Sep; 24(9):2563-2569. PMID: 28560598.
    Citations:    Fields:    Translation:Humans
  25. Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Paweletz CP, Demeo MK, Ramaiya NH, Overmoyer BA, Jain RK, Winer EP, Duda DG. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. Oncologist. 2017 01; 22(1):25-32. PMID: 27789775.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  26. Golshan M, Cirrincione CT, Sikov WM, Carey LA, Berry DA, Overmoyer B, Henry NL, Somlo G, Port E, Burstein HJ, Hudis C, Winer E, Ollila DW. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Res Treat. 2016 11; 160(2):297-304. PMID: 27704226.
    Citations: 3     Fields:    Translation:Humans
  27. Waks AG, Lennon J, Yadav BS, Hwang H, dSchapirael Carmen M, Johnson NB, Reynolds K, Schapira L, Gilman PB, Overmoyer B. Metastasis to the Cervix Uteri 15 Years After Treatment of Lobular Carcinoma of the Breast. Semin Oncol. 2015 Aug; 42(4):e81-94. PMID: 26320072.
    Citations: 1     Fields:    Translation:Humans
  28. Tolaney SM, Tan S, Guo H, Barry W, Van Allen E, Wagle N, Brock J, Larrabee K, Paweletz C, Ivanova E, Janne P, Overmoyer B, Wright JJ, Shapiro GI, Winer EP, Krop IE. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. Invest New Drugs. 2015 Oct; 33(5):1108-14. PMID: 26123926.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  29. Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM. Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015 Jun; 151(3):589-96. PMID: 25981899.
    Citations: 2     Fields:    Translation:Humans
  30. Warren LE, Guo H, Regan MM, Nakhlis F, Yeh ED, Jacene HA, Hirshfield-Bartek J, Overmoyer BA, Bellon JR. Inflammatory breast cancer and development of brain metastases: risk factors and outcomes. Breast Cancer Res Treat. 2015 May; 151(1):225-32. PMID: 25893587.
    Citations: 3     Fields:    Translation:Humans
  31. Warren LE, Guo H, Regan MM, Nakhlis F, Yeh ED, Jacene HA, Hirshfield-Bartek J, Overmoyer BA, Bellon JR. Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management. Ann Surg Oncol. 2015 Aug; 22(8):2483-91. PMID: 25791789.
    Citations: 2     Fields:    Translation:Humans
  32. Overmoyer B. Treatment with adjuvant endocrine therapy for early-stage breast cancer: is it forever? J Clin Oncol. 2015 Mar 10; 33(8):823-8. PMID: 25624431.
    Citations: 5     Fields:    Translation:Humans
  33. Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 08; 372(2):134-41. PMID: 25564897.
    Citations: 73     Fields:    Translation:HumansCTClinical Trials
  34. Nienhuis HH, Gaykema SB, Timmer-Bosscha H, Jalving M, Brouwers AH, Lub-de Hooge MN, van der Vegt B, Overmoyer B, de Vries EG, Schröder CP. Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets. Pharmacol Ther. 2015 Mar; 147:63-79. PMID: 25444756.
    Citations: 3     Fields:    Translation:HumansAnimals
  35. Yeh ED, Jacene HA, Bellon JR, Nakhlis F, Birdwell RL, Georgian-Smith D, Giess CS, Hirshfield-Bartek J, Overmoyer B, Van den Abbeele AD. What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach. Radiographics. 2013 Nov-Dec; 33(7):2003-17. PMID: 24224593.
    Citations: 3     Fields:    Translation:Humans
  36. Vaz-Luis I, Zeghibe CA, Frank ES, Sohl J, Washington KE, Silverman SG, Fonte JM, Mayer EL, Overmoyer BA, Richardson AL, Krop IE, Winer EP, Lin NU. Prospective clinical experience with research biopsies in breast cancer patients. Breast Cancer Res Treat. 2013 Nov; 142(1):203-9. PMID: 24113744.
    Citations: 4     Fields:    Translation:Humans
  37. Margalit DN, Sreedhara M, Chen YH, Catalano PJ, Nguyen PL, Golshan M, Overmoyer BA, Harris JR, Brock JE. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy. Ann Surg Oncol. 2013 Mar; 20(3):811-8. PMID: 22956068.
    Citations: 5     Fields:    Translation:Humans
  38. Overmoyer BA, Lee JM, Lerwill MF. Case records of the Massachusetts General Hospital. Case 17-2011. A 49-year-old woman with a mass in the breast and overlying skin changes. N Engl J Med. 2011 Jun 09; 364(23):2246-54. PMID: 21651397.
    Citations: 1     Fields:    Translation:Humans
  39. Chen WC, Kim J, Kim E, Silverman P, Overmoyer B, Cooper BW, Anthony S, Shenk R, Leeming R, Hanks SH, Lyons JA. A phase II study of radiotherapy and concurrent paclitaxel chemotherapy in breast-conserving treatment for node-positive breast cancer. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):14-20. PMID: 21035961.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  40. Overmoyer BA. Inflammatory breast cancer: novel preoperative therapies. Clin Breast Cancer. 2010 Feb; 10(1):27-32. PMID: 20133255.
    Citations: 4     Fields:    Translation:Humans
  41. Baar J, Silverman P, Lyons J, Fu P, Abdul-Karim F, Ziats N, Wasman J, Hartman P, Jesberger J, Dumadag L, Hohler E, Leeming R, Shenk R, Chen H, McCrae K, Dowlati A, Remick SC, Overmoyer B. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res. 2009 May 15; 15(10):3583-90. PMID: 19417018.
    Citations: 40     Fields:    Translation:HumansCTClinical Trials
  42. Storniolo AM, Pegram MD, Overmoyer B, Silverman P, Peacock NW, Jones SF, Loftiss J, Arya N, Koch KM, Paul E, Pandite L, Fleming RA, Lebowitz PF, Ho PT, Burris HA. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2008 Jul 10; 26(20):3317-23. PMID: 18490651.
    Citations: 32     Fields:    Translation:HumansCTClinical Trials
  43. Krishnamurthi SS, Brell JM, Hoppel CL, Egorin MJ, Weaver KC, Li X, Ingalls ST, Zuhowski EG, Schluchter MD, Dowlati A, Cooney MM, Gibbons J, Overmoyer BA, Ivy SP, Remick SC. Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. Cancer Chemother Pharmacol. 2009 Feb; 63(3):441-50. PMID: 18414865.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  44. Overmoyer B. Options for the treatment of patients with taxane-refractory metastatic breast cancer. Clin Breast Cancer. 2008 Mar; 8 Suppl 2:S61-70. PMID: 18637401.
    Citations: 3     Fields:    Translation:Humans
  45. Overmoyer B, Fu P, Hoppel C, Radivoyevitch T, Shenk R, Persons M, Silverman P, Robertson K, Ziats NP, Wasman JK, Abdul-Karim FW, Jesberger JA, Duerk J, Hartman P, Hanks S, Lewin J, Dowlati A, McCrae K, Ivy P, Remick SC. Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin. Clin Cancer Res. 2007 Oct 01; 13(19):5862-8. PMID: 17908980.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  46. Burstein HJ, Overmoyer B, Gelman R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Ivy P, Winer EP. Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules. Invest New Drugs. 2007 Apr; 25(2):161-4. PMID: 16969707.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  47. Kaur H, Silverman P, Singh D, Cooper BW, Fu P, Krishnamurthi S, Remick S, Overmoyer B. Toxicity and outcome data in a phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer (MBC). J Clin Oncol. 2006 Jun 20; 24(18_suppl):10623. PMID: 27952589.
    Citations:    
  48. Lyons JA, Silverman P, Remick S, Chen H, Leeming R, Shenk R, Fu P, Dumadag L, Escuro K, Overmoyer B. Toxicity results and early outcome data on a randomized phase II study of docetaxel ± bevacizumab for locally advanced, unresectable breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):3049. PMID: 27955260.
    Citations:    
  49. Kunos C, Latson L, Overmoyer B, Silverman P, Shenk R, Kinsella T, Lyons J. Breast conservation surgery achieving>or=2 mm tumor-free margins results in decreased local-regional recurrence rates. Breast J. 2006 Jan-Feb; 12(1):28-36. PMID: 16409584.
    Citations: 20     Fields:    Translation:Humans
  50. Cooper BW, Radivoyevitch T, Overmoyer BA, Shenk RR, Pham HT, Samuels JR, Parry MP, Silverman P. Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer. Breast Cancer Res Treat. 2006 Jun; 97(3):311-8. PMID: 16344915.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  51. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005 Aug 20; 23(24):5542-51. PMID: 16110015.
    Citations: 94     Fields:    Translation:HumansCTClinical Trials
  52. Burris HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005 Aug 10; 23(23):5305-13. PMID: 15955900.
    Citations: 150     Fields:    Translation:HumansCTClinical Trials
  53. Overmoyer B, Silverman P, Holder LW, Tripathy D, Henderson IC. Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clin Breast Cancer. 2005 Jun; 6(2):150-7. PMID: 16001993.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  54. Overmoyer B, Waintraub S, Kaufman PA, Doyle T, Moore H, Modiano M, Kroener J, Zhang X, Buzdar A, Demario M. Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):778. PMID: 27945742.
    Citations:    
  55. Singh D, Burns RL, Silverman P, Cooper BW, Krishnamurthi S, Fu P, Overmoyer BA. Trastuzumab-associated cardiac dysfunction. J Clin Oncol. 2005 Jun; 23(16_suppl):800. PMID: 27945079.
    Citations:    
  56. Storniolo AM, Burris H, Pegram M, Overmoyer B, Miller K, Jones S, Silverman P, Paul E, Loftiss J, Pandite L. A phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen. J Clin Oncol. 2005 Jun; 23(16_suppl):559. PMID: 27946466.
    Citations:    
  57. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005 Feb 01; 23(4):792-9. PMID: 15681523.
    Citations: 284     Fields:    Translation:HumansCTClinical Trials
  58. Spector NL, Xia W, Burris H, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol. 2005 Apr 10; 23(11):2502-12. PMID: 15684311.
    Citations: 105     Fields:    Translation:HumansCTClinical Trials
  59. Robert NJ, Vogel CL, Henderson IC, Sparano JA, Moore MR, Silverman P, Overmoyer BA, Shapiro CL, Park JW, Colbern GT, Winer EP, Gabizon AA. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin Oncol. 2004 Dec; 31(6 Suppl 13):106-46. PMID: 15717740.
    Citations: 9     Fields:    Translation:Humans
  60. Cooney MM, Tserng KY, Makar V, McPeak RJ, Ingalls ST, Dowlati A, Overmoyer B, McCrae K, Ksenich P, Lavertu P, Ivy P, Hoppel CL, Remick S. A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. Cancer Chemother Pharmacol. 2005 Mar; 55(3):295-300. PMID: 15538570.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  61. Cooney MM, Li X, McPeak RJ, Ingalls S, Krishnamurthi S, Brell J, Dowlati A, Overmoyer B, Hoppel C, Remick SC. Phase I pharmacokinetic trial of docetaxel and thalidomide: A regimen based on anti-angiogenic therapeutic principles. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3135. PMID: 28014861.
    Citations:    
  62. Burstein HJ, Overmoyer B, Gelman R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Winer EP. Rebeccamycin analog for refractory breast cancer: a randomized phase II trial. J Clin Oncol. 2004 Jul 15; 22(14_suppl):547. PMID: 28016577.
    Citations:    
  63. Overmoyer B, Silverman P, Leeming R, Shenk R, Lyons J, Ziats N, Jesberger J, Dumadag L, Remick S, Chen H. Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cance. J Clin Oncol. 2004 Jul 15; 22(14_suppl):727. PMID: 28013585.
    Citations:    
  64. Cooney MM, Radivoyevitch T, Dowlati A, Overmoyer B, Levitan N, Robertson K, Levine SL, DeCaro K, Buchter C, Taylor A, Stambler BS, Remick SC. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):96-100. PMID: 14734457.
    Citations: 31     Fields:    Translation:HumansCTClinical Trials
  65. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003 Aug 01; 21(15):2889-95. PMID: 12885806.
    Citations: 56     Fields:    Translation:HumansCTClinical Trials
  66. Overmoyer B. Combination chemotherapy for metastatic breast cancer: reaching for the cure. J Clin Oncol. 2003 Feb 15; 21(4):580-2. PMID: 12586790.
    Citations:    Fields:    Translation:Humans
  67. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002 Jun 15; 62(12):3408-16. PMID: 12067983.
    Citations: 70     Fields:    Translation:HumansCTClinical Trials
  68. Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW, Demetri GD. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res. 2002 Mar; 8(3):670-8. PMID: 11895894.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  69. Bolwell B, Vredenburgh J, Overmoyer B, Gilbert C, Chap L, Menchaca DM, Cruickshank S, Glaspy J. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant. 2000 Jul; 26(2):141-5. PMID: 10918423.
    Citations: 5     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  70. Overmoyer B. Breast cancer screening. Med Clin North Am. 1999 Nov; 83(6):1443-66, vi-vii. PMID: 10584602.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  71. Overmoyer BA. The breast cancer prevention trial (P-1 study). The role of tamoxifen in preventing breast cancer. Cleve Clin J Med. 1999 Jan; 66(1):33-40. PMID: 9926629.
    Citations:    Fields:    Translation:Humans
  72. Bolwell B, Goormastic M, Andresen S, Koo A, Wise K, Overmoyer B, Pohlman B, Kalaycio M. Variables associated with the platelet count 6 weeks after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant. 1998 Sep; 22(6):547-51. PMID: 9758341.
    Citations:    Fields:    Translation:HumansCells
  73. Bolwell BJ, Pohlman B, Andresen S, Kalaycio M, Goormastic M, Wise K, Wakeling A, Dannley R, Overmoyer B. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transplant. 1998 Feb; 21(4):369-73. PMID: 9509971.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  74. Abdel-Razeq H, Pohlman B, Andresen S, Kalaycio M, Overmoyer B, Wise K, Dannley R, DeMars D, Goormastic M, Bolwell B. A randomized study of multi-day infusion of autologous peripheral blood progenitor cells. Bone Marrow Transplant. 1998 Feb; 21(3):221-3. PMID: 9489643.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  75. Kalaycio M, Mendez Z, Pohlman B, Overmoyer B, Boparai N, Jones E, Bolwell B. Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy. J Cancer Res Clin Oncol. 1998; 124(5):265-9. PMID: 9645457.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  76. Bearman SI, Overmoyer BA, Bolwell BJ, Taylor CW, Shpall EJ, Cagnoni PJ, Mechling BE, Ronk B, Barón AE, Purdy MH, Ross M, Jones RB. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes. Bone Marrow Transplant. 1997 Dec; 20(11):931-7. PMID: 9422471.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  77. Isaacs C, Robert NJ, Bailey FA, Schuster MW, Overmoyer B, Graham M, Cai B, Beach KJ, Loewy JW, Kaye JA. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol. 1997 Nov; 15(11):3368-77. PMID: 9363868.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  78. Bolwell BJ, Kalaycio M, Goormastic M, Dannley R, Andresen SW, Lichtin A, Overmoyer B, Pohlman B. Progressive disease after ABMT for Hodgkin's disease. Bone Marrow Transplant. 1997 Nov; 20(9):761-5. PMID: 9384478.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  79. Bolwell BJ, Goormastic M, Andresen S, Overmoyer B, Pohlman B, Kalaycio M. Platelet transfusion requirements during autologous peripheral blood progenitor cell transplantation correlate with the pretransplant platelet count. Bone Marrow Transplant. 1997 Sep; 20(6):459-63. PMID: 9313878.
    Citations:    Fields:    Translation:HumansCells
  80. Bolwell B, Goormastic M, Dannley R, Andresen S, Overmoyer B, Mendez Z, Kalaycioglu M, DeMars D, Wise K, Pohlman B. G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10, and 16 micrograms/kg/day. Bone Marrow Transplant. 1997 Feb; 19(3):215-9. PMID: 9028548.
    Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
  81. Overmoyer BA. Ifosfamide in the treatment of breast cancer. Semin Oncol. 1996 Jun; 23(3 Suppl 6):38-41. PMID: 8677447.
    Citations:    Fields:    Translation:HumansCells
  82. Frost AR, Terahata S, Yeh IT, Siegel RS, Overmoyer B, Silverberg SG. An analysis of prognostic features in infiltrating lobular carcinoma of the breast. Mod Pathol. 1995 Oct; 8(8):830-6. PMID: 8552571.
    Citations: 3     Fields:    Translation:Humans
  83. Overmoyer BA. Chemotherapeutic palliative approaches in the treatment of breast cancer. Semin Oncol. 1995 Apr; 22(2 Suppl 3):2-9. PMID: 7537899.
    Citations: 2     Fields:    Translation:Humans
  84. Frost AR, Terahata S, Yeh IT, Siegel RS, Overmoyer B, Silverberg SG. The significance of signet ring cells in infiltrating lobular carcinoma of the breast. Arch Pathol Lab Med. 1995 Jan; 119(1):64-8. PMID: 7802556.
    Citations: 12     Fields:    Translation:Humans
  85. Overmoyer BA. Chemotherapy in the management of breast cancer. Cleve Clin J Med. 1995 Jan-Feb; 62(1):36-50. PMID: 7859401.
    Citations:    Fields:    Translation:Humans
  86. Fowble BL, Schultz DJ, Overmoyer B, Solin LJ, Fox K, Jardines L, Orel S, Glick JH. The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys. 1994 Aug 30; 30(1):23-33. PMID: 8083119.
    Citations: 48     Fields:    Translation:Humans
  87. Tumas KM, Poszgay JM, Avidan N, Ksiazek SJ, Overmoyer B, Blank KJ, Prystowsky MB. Loss of antigenic epitopes as the result of env gene recombination in retrovirus-induced leukemia in immunocompetent mice. Virology. 1993 Feb; 192(2):587-95. PMID: 7678475.
    Citations: 12     Fields:    Translation:AnimalsCells
  88. Tumas K, Overmoyer B, Clevenger CV, Blank KJ, Prystowsky MB. Murine leukemia virus infection in immunocompetent adult mice. Virology. 1993 Jan; 192(1):1-10. PMID: 8390745.
    Citations: 1     Fields:    Translation:AnimalsCells
  89. Meropol NJ, Overmoyer BA, Stadtmauer EA. High-dose chemotherapy with autologous stem cell support for breast cancer. Oncology (Williston Park). 1992 Dec; 6(12):53-60, 63; discussion 63-4, 69. PMID: 1467164.
    Citations: 2     Fields:    Translation:Humans
  90. Overmoyer BA, McLaren CE, Brittenham GM. Uniformity of liver density and nonheme (storage) iron distribution. Arch Pathol Lab Med. 1987 Jun; 111(6):549-54. PMID: 3579513.
    Citations: 6     Fields:    Translation:Humans
  91. Foreman D, Dusek F, Overmoyer B. The effects of gonadotropins on metabolism of isolated rat granulosa cells. Life Sci. 1984 Sep 17; 35(12):1273-9. PMID: 6090833.
    Citations:    Fields:    Translation:AnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Overmoyer's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (304)
Explore
_
Co-Authors (65)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.